基因編輯治療的全球市場

本報告調查了全球基因編輯治療市場，並提供了市場概況、市場影響因素和市場機會分析、新興技術和技術發展趨勢、管道分析、市場規模趨勢和預測、各個細分市場和地區。 、主要企業簡介等等。

目錄

第1章執行摘要

• 市場展望
• 調查範圍
• 市場概況

第2章 市場概況

• 基因組編輯工具的類型
• Meganucleases
• 鋅指核酸酶
• 轉錄活化劑樣效應核酸酶
• CRISPR/CRISPR相關蛋白9
• 基因編輯療法

第3章市場動態

• 市場動態簡介
• 市場促進因素
• 慢性病流行
• 罕見遺傳疾病增加
• 精準醫療
• 加強策略性舉措
• 市場限制因素
• 嚴格的法規結構和漫長的核准流程
• 治療費用上漲
• 不利事件和長期監測
• 缺乏熟練的工程師
• 脫靶效應
• 市場挑戰
• 專利糾紛
• 政府政策法規
• 道德問題
• 市場機會

第4章新興科技與發展

• 鹼基編輯
• 主要編輯
• Cas-Clover 和 Cas-FOKl
• CRISPR 干擾和 CRISPR 激活
• RNA編輯
• 人工智慧在基因組編輯的應用

第5章 管道分析

• 概述
• 臨床試驗分析：依技術分類
• 臨床試驗分析：依疾病分類
• 管道藥物名稱

第6章 專利分析

第7章市場分析

• Casgevy
• 市場概況
• 市場分析
• 區域市場
• 北美洲
• 歐洲
• 新興市場

第8章 競爭訊息

• 策略舉措
• 競爭格局

第9章基因編輯療法市場的永續性：環境、社會與管治(ESG) 視角

• 基因編輯公司的 ESG 實踐
• BCC 的結論

第10章附錄

• 調查方法
• 來源
• 縮寫詞
• 公司簡介
• ALLOGENE THERAPEUTICS
• BEAM THERAPEUTICS
• CARIBOU BIOSCIENCES INC.
• CRISPR THERAPEUTICS
• EDITAS MEDICINE
• INTELLIA THERAPEUTICS INC.
• PRECISION BIOSCIENCES
• SANGAMO THERAPEUTICS
• VERTEX PHARMACEUTICALS INC.
• VERVE THERAPEUTICS INC.
• VOR BIO

The report provides an overview of current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also include company profiles of key players, featuring detailed information regarding each company’s business segments, financials, product portfolios and recent developments. 

Report Scope:

This report highlights the current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also surveys the competitive environment, including coverage of the pipeline activities adopted by market players, and it includes market projections for 2029. Also included are company profiles of key players, featuring detailed information regarding each company's business segments, financials, product portfolios and recent developments.

Report Includes:

• 15 data tables and 42 additional tables
• An analysis of the current and future global markets for gene editing therapeutics
• Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue forecasts for the global gene editing therapeutics market, with market share analysis by region
• Discussion of the market dynamics, opportunities, and challenges, as well as emerging technologies
• Overview of sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG rankings, and consumer attitudes
• Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding
• Company profiles of major players within the industry, including CRISPR Therapeutics, Vertex Pharmaceuticals, and Intellia Therapeutics

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Introduction
• Genome-Editing Tool Types
• Meganucleases
• Zinc Finger Nucleases
• Transcription Activator-like Effector Nucleases
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9
• Gene editing Therapeutics

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Increasing Prevalence of Chronic Disease
• Increasing Prevalence of Rare Genetic Disorders
• Precision Medicine
• Increasing Strategic Initiatives
• Market Restraints
• Stringent Regulatory Frameworks and Time-Consuming Approval Processes
• High Cost of Treatment
• Adverse Events and Long-Term Monitoring
• Lack of Skilled Workforce
• Off-Target Impact
• Market Challenges
• Patent Disputes
• Governmental Policies and Regulations
• Ethical Issues
• Market Opportunities

Chapter 4 Emerging Technologies and Developments

• Introduction
• Base Editing
• Prime Editing
• Cas-Clover and Cas-FOKl
• CRISPR Interference and CRISPR Activation
• RNA Editing
• Artificial Intelligence in Genome Editing

Chapter 5 Pipeline Analysis

• Overview
• Clinical Trial Analysis Based on Technology
• Clinical Trial Analysis Based on Diseases
• Designations for Pipeline Drugs

Chapter 6 Patent Analysis

Chapter 7 Market Analysis

• Introduction
• Casgevy
• Market Overview
• Market Analysis
• Market by Region
• North America
• Europe
• Emerging Markets

Chapter 8 Competitive Intelligence

• Strategic Initiatives
• Competitive Landscape

Chapter 9 Sustainability in the Gene Editing Therapeutics Market: Environmental, Social and Governance (ESG) Perspectives

• Introduction
• ESG Practices in the Gene Editing Companies
• Concluding Remarks from BCC Research

Chapter 10 Appendix

• Methodology
• Sources
• Acronyms
• Company Profiles
• ALLOGENE THERAPEUTICS
• BEAM THERAPEUTICS
• CARIBOU BIOSCIENCES INC.
• CRISPR THERAPEUTICS
• EDITAS MEDICINE
• INTELLIA THERAPEUTICS INC.
• PRECISION BIOSCIENCES
• SANGAMO THERAPEUTICS
• VERTEX PHARMACEUTICALS INC.
• VERVE THERAPEUTICS INC.
• VOR BIO

List of Tables

• Summary Table : Global Market for Gene Editing Therapeutics, Through 2029
• Table 1 : Comparison of Genome-Editing Tools
• Table 2 : U.S. Adults Age 50 Years and Older with Multiple Chronic Conditions, 2020-2050
• Table 3 : Global Cases and Deaths Due to Various Cancers, 2022
• Table 4 : Gene Editing Index Ratings, 2020
• Table 5 : Rating Guide
• Table 6 : Comparison of Cas9-derived Proteins with Regular SpCas9
• Table 7 : Gene Editing Therapeutic Trials in Phase I, Till May 2024
• Table 8 : Gene Editing Therapeutic Trials in Phase I/II, II and III, Till May 2024
• Table 9 : Casgevy Label Expansion Studies, Till May 2024
• Table 10 : Examples of Some Pipeline Drugs and Their Designations, as of May 2024
• Table 11 : Patents on CRISPR Therapeutics, Published in 2021
• Table 12 : Patents on CRISPR Therapeutics, Published in 2022
• Table 13 : Patents on CRISPR Therapeutics, Published in 2023
• Table 14 : Global Market for Gene Editing Therapeutics, Through 2029
• Table 15 : Global Market for Gene Editing Therapeutics, by Region, Through 2029
• Table 16 : Strategic Initiatives in the Gene Editing Therapeutics Market, 2020-2024
• Table 17 : Venture Funding for Startups, 2023
• Table 18 : ESG Initiatives/Practices by Various Gene Editing Companies, 2023
• Table 19 : ESG Rankings for Companies in the Gene Editing Therapeutics Market, 2023
• Table 20 : Report Information Sources
• Table 21 : Glossary of Terms Used in This Report
• Table 22 : Allogene Therapeutics: Company Snapshot
• Table 23 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
• Table 24 : Allogene Therapeutics: News/Key Developments, 2020-2024
• Table 25 : Beam Therapeutics: Company Snapshot
• Table 26 : Beam Therapeutics: Financial Performance, FY 2022 and 2023
• Table 27 : Beam Therapeutics: News/Key Developments, 2021-2023
• Table 28 : Caribou Biosciences Inc.: Company Snapshot
• Table 29 : Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
• Table 30 : Caribou Biosciences Inc.: News/Key Developments, 2021-2024
• Table 31 : CRISPR Therapeutics: Company Snapshot
• Table 32 : CRISPR Therapeutics: Financial Performance, FY 2022 and 2023
• Table 33 : CRISPR Therapeutics: Product Portfolio
• Table 34 : CRISPR Therapeutics: News/Key Developments, 2021-2024
• Table 35 : Editas Medicine: Company Snapshot
• Table 36 : Editas Medicine: Financial Performance, FY 2022 and 2023
• Table 37 : Editas Medicine: News/Key Developments, 2022-2024
• Table 38 : Intellia Therapeutics Inc.: Company Snapshot
• Table 39 : Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023
• Table 40 : Intellia Therapeutics Inc.: News/Key Developments, 2021-2024
• Table 41 : Precision Biosciences: Company Snapshot
• Table 42 : Precision Biosciences: Financial Performance, FY 2022 and 2023
• Table 43 : Precision Biosciences: News/Key Developments, 2020-2024
• Table 44 : Sangamo Therapeutics: Company Snapshot
• Table 45 : Sangamo Therapeutics: Financial Performance, FY 2022 and 2023
• Table 46 : Sangamo Therapeutics: News/Key Developments, 2024
• Table 47 : Vertex Pharmaceuticals Inc.: Company Snapshot
• Table 48 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 49 : Vertex Pharmaceuticals Inc.: Product Portfolio
• Table 50 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024
• Table 51 : Verve Therapeutics Inc.: Company Snapshot
• Table 52 : Verve Therapeutics Inc.: Financial Performance, FY 2022 and 2023
• Table 53 : Verve Therapeutics Inc.: News/Key Developments, 2019-2024
• Table 54 : Vor Bio: Company Snapshot
• Table 55 : Vor Bio: Financial Performance, FY 2022 and 2023
• Table 56 : Vor Bio: News/Key Developments, 2020-2024

List of Figures

• Summary Figure : Global Market for Gene Editing Therapeutics, 2021-2029
• Figure 1 : Genome-Editing Outcomes
• Figure 2 : Endonucleases Used in Gene Editing Technologies
• Figure 3 : Advances in Therapeutic Strategies to Treat Life-Threatening Diseases
• Figure 4 : CRISPR/Cas9 Therapeutics Timeline, Since 1987-Present
• Figure 5 : CRISPR/Cas9 Therapeutics Delivery Platform
• Figure 6 : Delivery Method
• Figure 7 : Market Dynamics of Gene Editing Therapeutics Market
• Figure 8 : Genetic Disorders
• Figure 9 : Emerging Technologies in the Genome-Editing Therapeutics Market
• Figure 10 : Emerging Therapeutics Applications for RNA Editing by Cas Enzymes
• Figure 11 : Articles on Gene Editing Therapeutics in PubMed, 2004-2024
• Figure 12 : Share of Clinical Trials on the Genome-Editing Market, by Technology, Through May 2024
• Figure 13 : Genome-Editing Clinical Trials, by Diseases
• Figure 14 : Genome-Editing Clinical Trials, by Trial Phase
• Figure 15 : Genome-Editing Clinical Trials, by Trial Status
• Figure 16 : Patents Documented, by Top Owners, 2021-2024
• Figure 17 : Patents Documented, by Type, 2021-2024
• Figure 18 : Patents Documented, by Type, 2021-2024
• Figure 19 : Common Strategies Proposed for the Therapeutic Intervention for B-thalassemia and Sickle Cell Disease
• Figure 20 : Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 21 : Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 22 : Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023